BIND Therapeutics, Inc. announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins® that selectively bind and interact with identified targets.
As per agreement BIND will utilize Nanofitins® as targeting ligand components for ACCURINS® designed to bind immuno-oncology targets. ACCURINS® are polymeric nanoparticles that encapsulate and control the release of therapeutic payloads with diverse physical and chemical properties, including highly charged payloads such as oligonucleotides and molecularly targeted therapies that have previously been difficult to formulate in a nanoparticle.
The modular nature of our platform, including the ability to utilize targeting ligands that elicit a biological response and enhance disease tissue accumulation, will potentially allow us to develop ACCURINS® that cause tumor cell death and/or modulate the tumor microenvironment as a way to maximize clinical benefit for patients." said Jonathan Yingling, Ph.D., chief scientific officer, BIND Therapeutics.
